Navigation Links
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of life for patients.

For the complete press release, please visit : 0? mid=

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Certain statements in this announcement are forward-looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from those expressed and implied by the forward-looking statements

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
(Date:11/27/2015)... ... ... The print component of “Supporting Our Caregivers” is distributed ... Minneapolis, South Florida, with a circulation of approximately 250,000 copies and an estimated ... media strategy and across a network of top news sites and partner media ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
Breaking Medicine Technology: